Mostrar el registro sencillo del ítem
Clinical and Economic Evaluation after Adopting Contingent Cell-Free DNA Screening for Fetal Trisomies in South Spain.
dc.contributor.author | Sainz, José A. | |
dc.contributor.author | Torres, María | |
dc.contributor.author | Peral, Ignacio | |
dc.contributor.author | Granell, Reyes | |
dc.contributor.author | Vargas, Manuel | |
dc.contributor.author | Carrasco, Pilar | |
dc.contributor.author | García Mejido, José A. | |
dc.contributor.author | Santacruz Martín, Belén | |
dc.contributor.author | Gil Mira, María del Mar | |
dc.date.accessioned | 2020-11-11T12:22:38Z | |
dc.date.available | 2020-11-11T12:22:38Z | |
dc.date.issued | 2020 | |
dc.identifier.issn | 1015-3837 | spa |
dc.identifier.uri | http://hdl.handle.net/10641/2084 | |
dc.description.abstract | Contingent cell-free (cf) DNA screening on the basis of the first-trimester combined test (FCT) results has emerged as a cost-effective strategy for screening of trisomy 21 (T21). Objectives: To assess performance, patients’ uptake, and cost of contingent cfDNA screening and to compare them with those of the established FCT. Methods: This is a prospective cohort study including all singleton pregnancies attending to their FCT for screening of T21 at 2 university hospitals in South Spain. When the FCT risk was ≥1:50, there were major fetal malformations, or the nuchal translucency was ≥3.5 mm, women were recommended invasive testing (IT); if the risk was between 1:50 and 1:270, women were recommended cfDNA testing; and for risks bellow 1:270, no further testing was recommended. Detection rate (DR), false-positive rate (FPR), patients’ uptake, and associated costs were evaluated. Results: We analyzed 10,541 women, including 46 T21 cases. DR of our contingent strategy was 89.1% (41/46) at 1.4% (146/10,541) FPR. Uptake of cfDNA testing was 91.2% (340/373), and overall IT rate was 2.0%. The total cost of our strategy was €1,462,895.7, similar to €1,446,525.7 had cfDNA testing not been available. Conclusions: Contingent cfDNA screening shows high DR, low IT rate, and high uptake at a similar cost than traditional screening. | spa |
dc.language.iso | eng | spa |
dc.publisher | Fetal Diagnosis and Therapy | spa |
dc.rights | Atribución-NoComercial-SinDerivadas 3.0 España | * |
dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/3.0/es/ | * |
dc.subject | Cell-free DNA | spa |
dc.subject | Contingent screening | spa |
dc.subject | Combined test | spa |
dc.subject | Fetal trisomy | spa |
dc.subject | First trimester screening | spa |
dc.subject | Prenatal diagnosis | spa |
dc.title | Clinical and Economic Evaluation after Adopting Contingent Cell-Free DNA Screening for Fetal Trisomies in South Spain. | spa |
dc.type | journal article | spa |
dc.type.hasVersion | SMUR | spa |
dc.rights.accessRights | open access | spa |
dc.description.extent | 133 KB | spa |
dc.identifier.doi | 10.1159/000508306 | spa |
dc.relation.publisherversion | https://www.karger.com/Article/Abstract/508306 | spa |
Ficheros en el ítem
Ficheros | Tamaño | Formato | Ver |
---|---|---|---|
1.- Clinical and economic ... | 132.1Kb | Ver/ |
Este ítem aparece en la(s) siguiente(s) colección(ones)
-
MEDICINA [819]